论文部分内容阅读
目的研究脂质体介导的TK/GCV系统联合普通化疗用于治疗骨肉瘤细胞的可行性,初步研究GCV联合常用化疗药物多柔比星对骨肉瘤mg-63细胞的杀伤作用。方法订购重组质粒pIRES-EGFP-tk,培养和转染骨肉瘤细胞株mg-63,流式细胞仪分析和荧光倒置显微镜下观察细胞生长状态,观察GCV与多柔比星联合应用对mg-63的杀伤作用。结果成功将tk导入mg-63,并能稳定表达。荧光显微镜下观察mg-63(tk+)呈现绿色荧光。GCV(10mg/L)可明显抑制mg-63(tk+)的生长,多柔比星最低有效浓度为(1mg/L);联合应用GCV5mg/L与多柔比星0.25mg/L,即能表现出对mg-63细胞生长明显的抑制作用。结论脂质体介导的TK/GCV可对骨肉瘤细胞产生杀伤作用,与多柔比星联合应用可显著增强多柔比星对转化骨肉瘤细胞的杀伤作用,这将为骨肉瘤的新辅助化疗做出贡献。
Objective To study the feasibility of using liposome-mediated TK / GCV combined with general chemotherapy in the treatment of osteosarcoma cells and to study the cytotoxicity of GCV combined with commonly used chemotherapy drug doxorubicin on osteosarcoma cell line mg-63. Methods The recombinant plasmid pIRES-EGFP-tk was ordered and the osteosarcoma cell line mg-63 was cultured and transfected. The growth of osteosarcoma cell line MG-63 was observed by flow cytometry and fluorescence inverted microscopy. The killing effect. Results tk was successfully introduced into mg-63 and stably expressed. Under a fluorescence microscope, mg-63 (tk +) showed green fluorescence. GCV (10mg / L) significantly inhibited the growth of mg-63 (tk +), with the lowest effective concentration of doxorubicin being (1mg / L); combined with GCV5mg / L and doxorubicin 0.25mg / L, Inhibition of the growth of mg-63 cells was significantly inhibited. Conclusions Liposome-mediated TK / GCV can kill osteosarcoma cells. Combined with doxorubicin can significantly enhance the killing effect of doxorubicin on osteosarcoma cells, which will be a new assistant for osteosarcoma Chemotherapy to contribute.